Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine

OBJECTIVE: To evaluate the impact of fremanezumab on the severity and duration of remaining migraine attacks in patients with chronic migraine (CM) or episodic migraine (EM). BACKGROUND: Fremanezumab is a fully humanized monoclonal antibody (IgGΔa) that selectively targets calcitonin gene‐related pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Messoud, Cohen, Joshua M., Gandhi, Sanjay K., Du, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362007/
https://www.ncbi.nlm.nih.gov/pubmed/34115380
http://dx.doi.org/10.1111/head.14127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362007/
https://www.ncbi.nlm.nih.gov/pubmed/34115380
http://dx.doi.org/10.1111/head.14127

Ejemplares similares